| Federico, Massimo |
NCT00433433 / 2005-002765-37: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 1952 | Europe | ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual), Involved-Note Radiation Therapy, FDG-PET scan, F-18 fluorodeoxyglucose positron emission tomography scan | European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, Fondazione Italiana Linfomi ONLUS | Lymphoma | 12/11 | | | |
NCT03964480: Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. |
|
|
| Recruiting | N/A | 1000 | Europe, US, RoW | | Associazione Angela Serra per la ricerca sul cancro | Peripheral T-Cell Lymphoma | 01/23 | 07/25 | | |
| Renzo, Nicola Di |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
| Active, not recruiting | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 11/24 | 11/24 | | |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
| Recruiting | 2 | 120 | Europe | Pentaglobin | Gruppo Italiano Trapianto di Midollo Osseo | Septic Shock | 06/24 | 06/25 | | |
| Recruiting | 2 | 31 | Europe | Daratumumab plus chemotherapy according to the national treatment program | Gruppo Italiano Malattie EMatologiche dell'Adulto | T-Lymphocytic Leukemia, Acute | 10/29 | 10/29 | | |
NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients |
|
|
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Active, not recruiting | 2 | 68 | Europe | AG-120 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
| Recruiting | N/A | 1068 | Europe, RoW | all-trans retinoic acid (ATRA) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Leukemia | 12/20 | 12/20 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication |
|
|
| Active, not recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 10/23 | 06/24 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms |
|
|
| Recruiting | N/A | 237 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes | 03/25 | 03/25 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
|
|
| Recruiting | N/A | 32 | Europe | bone marrow and/or peripheral blood samples withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All | 05/24 | 05/24 | | |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
| Petrini, Mario |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies |
|
|
| Completed | 2 | 78 | Europe | GvHD prophylaxis | Gruppo Italiano Trapianto di Midollo Osseo | Myeloid Malignancies | 11/22 | 11/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Recruiting | 2 | 90 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 06/24 | 07/27 | | |
| Active, not recruiting | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Ferrarini, Manlio |
| No trials found |
| Morabito, Fortunato |
| No trials found |
| Gobbi, Paolo |
| No trials found |
| Pesce, Emanuela A |
| No trials found |
